IHS Chemical Week

People & Business :: Companies

Lonza Signs Manufacturing Deal with U.S. Pharma Firm

12:14 AM MDT | October 21, 2009 | Deepti Ramesh

Lonza says it has signed an agreement with Alnara Pharmaceuticals (Cambridge, MA), a company that develops and commercializes protein therapeutics for the treatment of metabolic diseases, to manufacture Alnara’s lead product liprotamase - an oral, pancreatic enzyme replacement therapy (PERT) for patients with pancreatic insufficiency. Lonza will provide microbial fermentation, process optimization, technical and regulatory support, under the terms of the deal, and all related production will be conducted in Lonza’s FDA registered facility at...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa